Tekmira Pharmaceuticals Corp (TKMR) (TKMR)

[surf1944]

8:02AM Tekmira Pharma believes that current funds on hand, plus expected income will be sufficient to continue product development into 2015 (TKMR) 4.75 : Co announced its key product development, corporate, and partner milestones for 2013. "Looking at our partners, we anticipate results from Alnylam's ALN-TTR02 Phase II trial in mid-2013 and the initiation of a Phase III trial by the end of 2013 and we expect to receive $10 million in milestone payments from Alnylam in 2013. In addition, we are entitled to future royalty payments based on sales of Marqibo, which was recently approved by the FDA. With clarity around the intellectual property protecting our LNP technology platform, we are well-positioned to pursue product, platform and strategic partnering deals," added Dr. Murray.

Financial guidance
Tekmira believes that current funds on hand, plus expected income, including payments received from Alnylam in Q4 2012 and other funds from collaborative partners and the U.S. Government, will be sufficient to continue product development into 2015.